C-peptide as a biomarker in preeclampsia
Preeclampsia (PE) is a syndrome exclusive to human pregnancy and responsible for high perinatal morbidity and mortality, whose manifestations include hypertension, proteinuria, and edema. There is evidence that PE incidence is four times higher in diabetic type 1 women than in non-diabetic women; and increases in women with metabolic syndrome and insulin resistance. C-peptide is a 31 amino acid residue polypeptide part of the proinsulin, which is enzymatically cleaved into insulin and C-peptide molecule. Both are simultaneously secreted in equimolar concentrations into blood, thus serum C-peptide level might reflect real insulin production. Little is known about the relationship between circulating levels of C-peptide and the increase in blood pressure in PE. For this reason, we assessed serum levels of C-peptide, and insulin in women with normal pregnancy and with PE, in a population of 30 Venezuelan women. Serum samples were evaluated by multiplex microsphere analysis (Bio-Plex Pro Assays). Our results show increased insulin and C-peptide serum levels in women with PE. Spearman correlation analysis in all subjects showed a positive association between SBP and C-peptide (r= 0.4841; P<0.0251) and insulin (r= 0.4386; P<0.0221), associated with a positive correlation between SBP and proteinuria and glucose. Our results suggest that an increase in C-peptide could be associated with the development of hypertension and insulin resistance in PE. Therefore, the quantification of this peptide could be a promising biomarker to predict the onset of pregnancy-induced hypertension.